Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
He walked on the moon in 1972. This is his advice for the Artemis II astronauts. - 2Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- 34 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- 4Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- 5Arctic sea ice just dropped to an alarming new low
- 5 VIP Voice Exhibitions in Energized Movies
- Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- 10 High priority Contraptions for Tech Aficionados
- 6 Web-based Course Stages for Successful Learning and Educating
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- How AI fixed the James Webb Space Telescope's blurry vision
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- Like 'accelerating from stationary to supersonic flight': Europe's Hera probe boosts speed, stays on course for November asteroid rendezvous
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
